New hope for Hard-to-Treat colorectal cancer: targeted drug shows promise
NCT ID NCT07213570
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial is testing the drug regorafenib as a second-line treatment for people with advanced colorectal cancer that has a specific mutation in the RAS gene. The study aims to see if a personalized, less intensive treatment approach can help control the cancer and improve quality of life. About 60 participants will receive either regorafenib or standard second-line therapy, and researchers will track how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Regorafenib
What this could lead to
If successful, this could offer a less intensive treatment option for people with a specific type of advanced colorectal cancer, potentially improving quality of life while controlling the disease.
What could go wrong
This is a small, early-phase study (phase 2) with only 60 participants, so results may not apply to everyone. The drug can cause side effects like fatigue, hand-foot skin reaction, and liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituto Nazionale Tumori | "Fondazione Pascale"
RECRUITINGNaples, Italy, Italy